Fernwood Investment Management LLC Cuts Stock Position in Cencora, Inc. (NYSE:COR)

Fernwood Investment Management LLC decreased its holdings in shares of Cencora, Inc. (NYSE:CORFree Report) by 3.3% during the third quarter, HoldingsChannel reports. The institutional investor owned 10,090 shares of the company’s stock after selling 340 shares during the period. Fernwood Investment Management LLC’s holdings in Cencora were worth $2,271,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently added to or reduced their stakes in the stock. New Millennium Group LLC purchased a new stake in Cencora during the 2nd quarter worth approximately $26,000. TCTC Holdings LLC acquired a new stake in shares of Cencora in the first quarter worth approximately $29,000. TFO Wealth Partners LLC purchased a new stake in shares of Cencora during the first quarter worth approximately $30,000. MFA Wealth Advisors LLC acquired a new position in Cencora in the 2nd quarter valued at $30,000. Finally, Concord Wealth Partners purchased a new position in Cencora in the 3rd quarter valued at $30,000. Institutional investors and hedge funds own 97.52% of the company’s stock.

Insiders Place Their Bets

In other news, Chairman Steven H. Collis sold 21,509 shares of Cencora stock in a transaction on Tuesday, October 22nd. The stock was sold at an average price of $235.80, for a total value of $5,071,822.20. Following the completion of the sale, the chairman now directly owns 285,088 shares of the company’s stock, valued at approximately $67,223,750.40. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. In other Cencora news, Chairman Steven H. Collis sold 21,509 shares of the business’s stock in a transaction dated Tuesday, October 22nd. The shares were sold at an average price of $235.80, for a total transaction of $5,071,822.20. Following the sale, the chairman now directly owns 285,088 shares in the company, valued at $67,223,750.40. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Silvana Battaglia sold 1,473 shares of the stock in a transaction dated Tuesday, August 6th. The stock was sold at an average price of $242.69, for a total transaction of $357,482.37. Following the sale, the executive vice president now directly owns 10,948 shares in the company, valued at $2,656,970.12. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. 15.80% of the stock is owned by insiders.

Cencora Trading Up 2.7 %

NYSE:COR traded up $6.19 on Friday, reaching $234.27. The company’s stock had a trading volume of 1,619,694 shares, compared to its average volume of 1,405,605. The firm has a market cap of $46.16 billion, a price-to-earnings ratio of 25.44, a price-to-earnings-growth ratio of 1.46 and a beta of 0.44. The company has a quick ratio of 0.55, a current ratio of 0.89 and a debt-to-equity ratio of 3.93. Cencora, Inc. has a 12-month low of $184.00 and a 12-month high of $247.66. The stock has a 50 day moving average price of $231.39 and a 200 day moving average price of $230.65.

Cencora (NYSE:CORGet Free Report) last posted its quarterly earnings data on Wednesday, July 31st. The company reported $3.34 earnings per share for the quarter, topping analysts’ consensus estimates of $3.18 by $0.16. The firm had revenue of $74.20 billion during the quarter, compared to analysts’ expectations of $73.32 billion. Cencora had a net margin of 0.65% and a return on equity of 266.60%. The firm’s quarterly revenue was up 10.8% on a year-over-year basis. During the same quarter last year, the company posted $2.92 EPS. On average, equities analysts anticipate that Cencora, Inc. will post 13.64 EPS for the current fiscal year.

Analysts Set New Price Targets

COR has been the subject of a number of recent research reports. Wells Fargo & Company increased their target price on shares of Cencora from $236.00 to $249.00 and gave the company an “equal weight” rating in a research report on Thursday, August 1st. Leerink Partners decreased their target price on shares of Cencora from $277.00 to $275.00 and set an “outperform” rating on the stock in a research note on Monday, October 7th. StockNews.com lowered Cencora from a “strong-buy” rating to a “buy” rating in a research report on Friday, September 20th. Robert W. Baird cut their price target on Cencora from $287.00 to $283.00 and set an “outperform” rating for the company in a report on Friday, September 6th. Finally, JPMorgan Chase & Co. boosted their price objective on Cencora from $280.00 to $287.00 and gave the stock an “overweight” rating in a research note on Wednesday, August 21st. Three research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $259.44.

View Our Latest Report on Cencora

About Cencora

(Free Report)

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.

Further Reading

Want to see what other hedge funds are holding COR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cencora, Inc. (NYSE:CORFree Report).

Institutional Ownership by Quarter for Cencora (NYSE:COR)

Receive News & Ratings for Cencora Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cencora and related companies with MarketBeat.com's FREE daily email newsletter.